Clopidogrel resistance after renal transplantation

Adam Varga, Barbara Sandor, Karoly Kalmar Nagy, Dora Praksch, Katalin Gombos, Andras Toth, K. Tóth, Peter Szakaly

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Leading causes of mortality and morbidity after kidney transplantation are cardiovascular diseases. One of the fundamentals of their prevention is the inhibition of platelet aggregation. Resistance to anti-platelet agents is a well-established phenomenon; however, its causes are yet to be clarified. Patients and Methods: Forty post-transplant patients, who received 75 mg clopidogrel q.d. as a prophylactic measure, were examined using optical aggregometry. Subsequently, logistic regression analysis was performed with 24 variables in order to expose possible causes of resistance. Results: Sixty percent of patients (24) were resistant to clopidogrel therapy; effective thrombocyte inhibition could only be shown in 40% of them (16). Significant correspondence between resistance and variables could not be found. Conclusion: Clopidogrel resistance is expected to occur on a large scale in patients who underwent kidney transplant surgery. Thus, a key component of preventive therapy, which stresses the importance of discovering the cause of resistance so as to decrease mortality rates, is missing.

Original languageEnglish
Pages (from-to)301-304
Number of pages4
JournalIn Vivo
Volume29
Issue number2
Publication statusPublished - Mar 1 2015

Fingerprint

clopidogrel
Kidney Transplantation
Transplants
Platelets
Blood Platelets
Regression analysis
Surgery
Mortality
Logistics
Agglomeration
Platelet Aggregation
Cardiovascular Diseases
Logistic Models
Regression Analysis
Morbidity
Kidney
Therapeutics

Keywords

  • Cardiovascular complication
  • Clopidogrel resistance
  • Platelet aggregation
  • Transplantation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Varga, A., Sandor, B., Nagy, K. K., Praksch, D., Gombos, K., Toth, A., ... Szakaly, P. (2015). Clopidogrel resistance after renal transplantation. In Vivo, 29(2), 301-304.

Clopidogrel resistance after renal transplantation. / Varga, Adam; Sandor, Barbara; Nagy, Karoly Kalmar; Praksch, Dora; Gombos, Katalin; Toth, Andras; Tóth, K.; Szakaly, Peter.

In: In Vivo, Vol. 29, No. 2, 01.03.2015, p. 301-304.

Research output: Contribution to journalArticle

Varga, A, Sandor, B, Nagy, KK, Praksch, D, Gombos, K, Toth, A, Tóth, K & Szakaly, P 2015, 'Clopidogrel resistance after renal transplantation', In Vivo, vol. 29, no. 2, pp. 301-304.
Varga A, Sandor B, Nagy KK, Praksch D, Gombos K, Toth A et al. Clopidogrel resistance after renal transplantation. In Vivo. 2015 Mar 1;29(2):301-304.
Varga, Adam ; Sandor, Barbara ; Nagy, Karoly Kalmar ; Praksch, Dora ; Gombos, Katalin ; Toth, Andras ; Tóth, K. ; Szakaly, Peter. / Clopidogrel resistance after renal transplantation. In: In Vivo. 2015 ; Vol. 29, No. 2. pp. 301-304.
@article{d41228311a46433abc4f9a09348262d2,
title = "Clopidogrel resistance after renal transplantation",
abstract = "Background: Leading causes of mortality and morbidity after kidney transplantation are cardiovascular diseases. One of the fundamentals of their prevention is the inhibition of platelet aggregation. Resistance to anti-platelet agents is a well-established phenomenon; however, its causes are yet to be clarified. Patients and Methods: Forty post-transplant patients, who received 75 mg clopidogrel q.d. as a prophylactic measure, were examined using optical aggregometry. Subsequently, logistic regression analysis was performed with 24 variables in order to expose possible causes of resistance. Results: Sixty percent of patients (24) were resistant to clopidogrel therapy; effective thrombocyte inhibition could only be shown in 40{\%} of them (16). Significant correspondence between resistance and variables could not be found. Conclusion: Clopidogrel resistance is expected to occur on a large scale in patients who underwent kidney transplant surgery. Thus, a key component of preventive therapy, which stresses the importance of discovering the cause of resistance so as to decrease mortality rates, is missing.",
keywords = "Cardiovascular complication, Clopidogrel resistance, Platelet aggregation, Transplantation",
author = "Adam Varga and Barbara Sandor and Nagy, {Karoly Kalmar} and Dora Praksch and Katalin Gombos and Andras Toth and K. T{\'o}th and Peter Szakaly",
year = "2015",
month = "3",
day = "1",
language = "English",
volume = "29",
pages = "301--304",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Clopidogrel resistance after renal transplantation

AU - Varga, Adam

AU - Sandor, Barbara

AU - Nagy, Karoly Kalmar

AU - Praksch, Dora

AU - Gombos, Katalin

AU - Toth, Andras

AU - Tóth, K.

AU - Szakaly, Peter

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: Leading causes of mortality and morbidity after kidney transplantation are cardiovascular diseases. One of the fundamentals of their prevention is the inhibition of platelet aggregation. Resistance to anti-platelet agents is a well-established phenomenon; however, its causes are yet to be clarified. Patients and Methods: Forty post-transplant patients, who received 75 mg clopidogrel q.d. as a prophylactic measure, were examined using optical aggregometry. Subsequently, logistic regression analysis was performed with 24 variables in order to expose possible causes of resistance. Results: Sixty percent of patients (24) were resistant to clopidogrel therapy; effective thrombocyte inhibition could only be shown in 40% of them (16). Significant correspondence between resistance and variables could not be found. Conclusion: Clopidogrel resistance is expected to occur on a large scale in patients who underwent kidney transplant surgery. Thus, a key component of preventive therapy, which stresses the importance of discovering the cause of resistance so as to decrease mortality rates, is missing.

AB - Background: Leading causes of mortality and morbidity after kidney transplantation are cardiovascular diseases. One of the fundamentals of their prevention is the inhibition of platelet aggregation. Resistance to anti-platelet agents is a well-established phenomenon; however, its causes are yet to be clarified. Patients and Methods: Forty post-transplant patients, who received 75 mg clopidogrel q.d. as a prophylactic measure, were examined using optical aggregometry. Subsequently, logistic regression analysis was performed with 24 variables in order to expose possible causes of resistance. Results: Sixty percent of patients (24) were resistant to clopidogrel therapy; effective thrombocyte inhibition could only be shown in 40% of them (16). Significant correspondence between resistance and variables could not be found. Conclusion: Clopidogrel resistance is expected to occur on a large scale in patients who underwent kidney transplant surgery. Thus, a key component of preventive therapy, which stresses the importance of discovering the cause of resistance so as to decrease mortality rates, is missing.

KW - Cardiovascular complication

KW - Clopidogrel resistance

KW - Platelet aggregation

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84928104578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928104578&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 301

EP - 304

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 2

ER -